With economic pressures affecting the healthcare industry, the market access team at Roche Denmark have found it increasingly important to be able to demonstrate the economic value of their products to different stakeholders.
When the company launched new subcutaneous formulations of Herceptin and MabThera, they decided to create a value communication tool that would demonstrate the potential resource savings associated with choosing the new products, taking into account all the relevant clinical and administrative factors.
"We wanted to find a way to demonstrate the value of using the product in this new form, in a simple and comprehensive manner. This would send a powerful message out to payers and prescribers, and incentivize the switch in the market." — Katrin Magnusdottir, Pricing & Tender Manager